Considering that PD-1 is the predominant target in melanoma immunotherapy, various PD-1 inhibitors, including nivolumab [57, 58], pembrolizumab [59–61], and toripalimab [62, 63], have been extensively utilized in clinical settings for MM treatment. Here, PDCD1 is linked to Miyoshi myopathy.